These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 24834924)

  • 21. Mepolizumab effectiveness and identification of super-responders in severe asthma.
    Harvey ES; Langton D; Katelaris C; Stevens S; Farah CS; Gillman A; Harrington J; Hew M; Kritikos V; Radhakrishna N; Bardin P; Peters M; Reynolds PN; Upham JW; Baraket M; Bowler S; Bowden J; Chien J; Chung LP; Grainge C; Jenkins C; Katsoulotos GP; Lee J; McDonald VM; Reddel HK; Rimmer J; Wark PAB; Gibson PG
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32139455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma.
    Ververeli K; Chipps B
    Ann Allergy Asthma Immunol; 2004 May; 92(5):512-22. PubMed ID: 15191019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mepolizumab treatment for asthma.
    Robinson DS
    Expert Opin Biol Ther; 2013 Feb; 13(2):295-302. PubMed ID: 22998420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study.
    Enríquez-Rodríguez AI; Hermida Valverde T; Romero Álvarez P; López-González FJ; Gullón Blanco JA; Expósito Villegas AR; Escobar Fernández MJ; Beristáin Urquiza AM; Alonso Fernández MÁ; Gutiérrez Rodríguez M; Castaño De Las Pozas G; Jiménez Pérez J; Fernández Mellado R; García Clemente MM; Casan Clara P
    J Asthma; 2022 May; 59(5):1005-1011. PubMed ID: 33653213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?
    Menzella F; Latorre M; Ruggiero P; Bagnasco D; Heffler E
    Expert Opin Biol Ther; 2019 Jul; 19(7):601-606. PubMed ID: 31033373
    [No Abstract]   [Full Text] [Related]  

  • 27. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Appropriate use of oral corticosteroids for severe asthma.
    Ramsahai JM; Wark PA
    Med J Aust; 2018 Jul; 209(S2):S18-S21. PubMed ID: 30453868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience.
    Matucci A; Vivarelli E; Bormioli S; Francesca N; Chiccoli F; Valentina M; Francesca G; Oliviero R; Parronchi P; Vultaggio A
    J Asthma; 2023 Jan; 60(1):158-166. PubMed ID: 35112934
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of oral corticosteroids in the treatment of acute wheezing episodes in asthmatic preschoolers: Systematic review with meta-analysis.
    Castro-Rodriguez JA; Beckhaus AA; Forno E
    Pediatr Pulmonol; 2016 Aug; 51(8):868-76. PubMed ID: 27074244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies.
    Casale TB; Burnette A; Bourdin A; Howarth P; Hahn B; Stach-Klysh A; Khurana S
    Ther Adv Respir Dis; 2022; 16():17534666221107313. PubMed ID: 35972211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.
    Özdel Öztürk B; Yavuz Z; Eraslan D; Mungan D; Demirel YS; Aydın Ö; Sin BA; Bavbek S
    Int Arch Allergy Immunol; 2022; 183(5):526-538. PubMed ID: 34915496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid-dependent asthma in Sweden.
    Andersson M; Janson C; Kristensen T; Szende A; Golam S
    J Med Econ; 2020 Aug; 23(8):877-884. PubMed ID: 32324093
    [No Abstract]   [Full Text] [Related]  

  • 34. Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry.
    Thomas D; Harvey ES; McDonald VM; Stevens S; Upham JW; Katelaris CH; Kritikos V; Gillman A; Harrington J; Hew M; Bardin P; Peters M; Reynolds PN; Langton D; Baraket M; Bowden JJ; Bowler S; Chien J; Chung LP; Farah CS; Grainge C; Jenkins C; Katsoulotos GP; Lee J; Radhakrishna N; Reddel HK; Rimmer J; Sivakumaran P; Wark PAB; Gibson PG
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2715-2724.e5. PubMed ID: 33545399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
    Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Burden of Chronic Oral Corticosteroid Use by Adults with Persistent Asthma.
    Zeiger RS; Schatz M; Li Q; Chen W; Khatry DB; Tran TN
    J Allergy Clin Immunol Pract; 2017; 5(4):1050-1060.e9. PubMed ID: 28215604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan.
    Nagase H; Tamaoki J; Suzuki T; Nezu Y; Akiyama S; Cole AL; Yang S; Mu G; Katsumata M; Komatsubara M; Alfonso-Cristancho R
    Pulm Pharmacol Ther; 2022 Aug; 75():102130. PubMed ID: 35714883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence.
    Calzetta L; Aiello M; Frizzelli A; Bertorelli G; Rogliani P; Chetta A
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Summaries for patients. Omalizumab therapy for patients with severe asthma.
    Ann Intern Med; 2011 May; 154(9):I28. PubMed ID: 21536934
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma.
    Fish JE; Karpel JP; Craig TJ; Bensch GW; Noonan M; Webb DR; Silverman B; Schenkel EJ; Rooklin AR; Ramsdell JW; Nathan R; Leflein JG; Grossman J; Graft DF; Gower RG; Garay SM; Frigas E; Degraff AC; Bronsky EA; Bernstein DI; Berger W; Shneyer L; Nolop KB; Harrison JE
    J Allergy Clin Immunol; 2000 Nov; 106(5):852-60. PubMed ID: 11080706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.